snapshot NATIONAL FORENSIC LABORATORY INFORMATION SYSTEM DRUG June 2020 Newly Reported Drugs: The following drugs were reported to NFLIS-Drug for the first time between April 1, 2020, and June 30, 2020, and were submitted to a NFLIS participating laboratory on or after April 1, 2019.
Northeast South 4-Anilino-1-Boc-piperidine
Phenethyl 4-ANPP 2-Fluoro viminol MMB-4en-PINACA
ADB-BUTINACA
Snapshot of Drug Reports Top 5 Reported Drugs 257,376 Synthetic Cathinones 2,820 Selected Benzodiazepines 10,796 Received by NFLIS-Drug Methamphetamine 115,410 Eutylone 2,116 Flualprazolam 963 The tables on the right present Cannabis/THC 54,601 N-Ethylpentylone 135 Etizolam 832 1 the top five drug reports in each Cocaine 39,891 BMDP 135 Clonazolam 195 2 category received by NFLIS-Drug Heroin 25,263 Butylpentylone 99 Flubromazolam 81 Adinazolam 65 between April 1, 2020, and June Fentanyl 22,211 alpha-PiHP 83 30, 2020, that were submitted to a NFLIS participating laboratory Synthetic Cannabinoids 4,237 Narcotic Analgesics 16,953 Other Selected Drugs 4,507 on or after April 1, 2019. Fluoro-MDMB-PICA2 1,884 Oxycodone 4,820 MDMA 1,478 Fluoro-MDMB-BINACA2 633 Buprenorphine 4,780 Gabapentin 968 1 BMDP = 3,4-Methylenedioxy-N-benzylcathinone. MDMB-4en-PINACA 445 Hydrocodone 3,085 Lysergic acid diethylamide (LSD) 957 2 Includes all positional and nonspecified isomers as reported by participating laboratories. Fluoro-ADB2 98 Tramadol 1,721 Psilocin 825 FUB-AMB 96 Morphine 760 Xylazine 279
Emerging Drug Trends The charts below depict the number of reports (y axis) for selected emerging drugs that were submitted to a NFLIS participating laboratory from November 2018 through March 2020 and received by NFLIS-Drug by June 30, 2020.
35 20 APP-BINACA 3,4-Methylenedioxy PV8 0 0
80 20 Butylpentylone2 N-Ethylheptedrone 0 0
200 20 MDMB-4en-PINACA N-Butylhexedrone 0 0
20 20 Isotonitazene 5-MeO-DBT 0 0 Nov Jul Mar Nov Jul Mar ’18 ’19 ’20 ’18 ’19 ’20
Data Disclaimer: Substances identified by Federal, State, and local laboratories are included in the raw counts of drug reports received by NFLIS-Drug. Raw counts have not undergone any adjustments to account for laboratory nonresponse. Data for this publication were exported from the NFLIS-Drug database in July 2020 and include drug reports received by NFLIS-Drug through the end of June 2020. Because of the time it takes for a laboratory to analyze seized material and transfer the data to the NFLIS database, the data in this publication—unlike those reported in an Annual or Midyear Report—are not comprehensive and do not reflect total counts of drugs analyzed over the period. More information on NFLIS data limitations can be found in the NFLIS Questions and Answers guide: https://www.nflis.deadiversion.usdoj.gov/DesktopModules/ ReportDownloads/Reports/2k17NFLISQA.pdf. NFLIS reports are available at https://www.nflis.deadiversion.usdoj.gov/Reports.aspx. Questions and comments: [email protected] DEA PRB 08-04-20-25